Objective: To evaluate the effectiveness and safety of Naoxintong for treating patients with clopidogrel resistance after percutaneous coronary intervention (PCI). Methods: 108 patients with clopidogrel resistance after PCI were randomly divided into clopidogrel group, Naoxintong group and ticagrelor group with 36 patients in each group. After PCI, the patients in clopidogrel group took 150mg (qd) clopidogrel; the patients in Naoxintong group took 150mg (qd) clopidogrel and 0.8mg Naoxintong capsule (tid); the patients in ticagrelor group took 90mg ticagrelor(bid). The platelet aggregation rate (1 week and 1month after treatment) and adverse reactions of patients in 3 groups were recorded. Results: The platelet aggregation rate of patients in Naoxintong group and ticagrelor group after treatment were all obviously lower than that before treatment (P<0.05); also obviously lower than clopidogrel group after treatment (P<0.05). In addition, the platelet aggregation rate of patients in ticagrelor group 1 month after treatment was obviously lower than Naoxintong group (P<0.05). There was no significant difference in incidence rate of bleeding events between the three groups (P<0.05); But the incidence rate of dyspnea of ticagrelor group (11.11%, 4/36) was obviously higher than clopidogrel group and Naoxintong group (P<0.05). Conclusions: Naoxintong can improve the antiplatelet effects of CR patients after PCI and has less side effects,so it is worthy of clinical expansion.